Pollen & Mold

Atlanta Allergy Pollen Count for 12/12/2019: 2
more info

Trees

Grass

Weeds


Mold Activity for 12/12/2019:

Sign up for our Pollen Count email.

Newsletter Sign Up

Stay up to date with the latest news from Atlanta Allergy & Asthma.

Peanut Allergy Drug Slated for 2018

Updated on Wednesday, July 1, 2015

We at Atlanta Allergy & Asthma are please to see that the FDA has decided to fast-track the studies for these potential therapies for patients with peanut allergy. The preliminary data looks promising for this novel system for delivery of allergen immunotherapy.

A French biopharmaceutical company has developed a wearable skin patch that helps allergy patients increase their tolerance to peanuts. Although the drug, Viaskin Peanut, is not yet available to Americans, it is set to enter Phase III trials with the U.S. Food and Drug Administration by the end of 2015. The developing company, DBV Technologies, has plans to begin selling the product in the United States some time during the first half of 2018.

Another company, the newly renamed U.S.-based Aimmune Therapeutics, is also developing a drug for those with a peanut allergy. The corporation recently received the same FDA approval to fast-track testing.

To read the entire article, please click here.